Release
📈 Stocks
Orion and Bayer Report 58% Metastasis Risk Reduction in Prostate Cancer Trial
(just now)
Phase III data for darolutamide shows a 58% reduction in metastasis risk for high-risk prostate cancer patients, bolstering the clinical outlook for…